NASDAQ:AMRN

Amarin Competitors

$5.02

+0.01 (+0.20 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.86

Now: $5.02▼

$5.07

50-Day Range

$5.01

MA: $6.18▼

$6.95

52-Week Range

$3.36

Now: $5.02▼

$9.25

Volume4.41 million shs

Average Volume6.89 million shs

Market Capitalization$1.98 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.58

Amarin (NASDAQ:AMRN) Vs. RARE, ARWR, GWPH, ASND, TGTX, and IONS

Should you be buying AMRN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Amarin, including Ultragenyx Pharmaceutical (RARE), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), and Ionis Pharmaceuticals (IONS).

Amarin vs. Ultragenyx Pharmaceutical Stock

Amarin (NASDAQ:AMRN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

37.8% of Amarin shares are held by institutional investors. 2.8% of Amarin shares are held by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Amarin and Ultragenyx Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	0	3	8	0	2.73
Ultragenyx Pharmaceutical	0	6	8	0	2.57

Amarin presently has a consensus target price of $11.1818, suggesting a potential upside of 122.75%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, suggesting a potential upside of 20.68%. Given Amarin's stronger consensus rating and higher possible upside, equities analysts clearly believe Amarin is more favorable than Ultragenyx Pharmaceutical.

Risk & Volatility

Amarin has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500.

Profitability

This table compares Amarin and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-2.69%	-2.70%	-1.72%
Ultragenyx Pharmaceutical	-119.19%	-50.69%	-26.87%

Earnings & Valuation

This table compares Amarin and Ultragenyx Pharmaceutical's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$429.76 million	4.60	$-22,650,000.00	($0.07)	-71.71
Ultragenyx Pharmaceutical	$103.71 million	70.18	$-402,730,000.00	($7.36)	-14.77

Amarin has higher revenue and earnings than Ultragenyx Pharmaceutical. Amarin is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Amarin beats Ultragenyx Pharmaceutical on 10 of the 13 factors compared between the two stocks.

Amarin vs. Arrowhead Pharmaceuticals Stock

Amarin (NASDAQ:AMRN) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Amarin and Arrowhead Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-2.69%	-2.70%	-1.72%
Arrowhead Pharmaceuticals	-96.09%	-17.37%	-15.19%

Earnings & Valuation

This table compares Amarin and Arrowhead Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$429.76 million	4.60	$-22,650,000.00	($0.07)	-71.71
Arrowhead Pharmaceuticals	$87.99 million	79.80	$-84,550,000.00	($0.84)	-80.54

Amarin has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amarin has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500.

Institutional & Insider Ownership

37.8% of Amarin shares are held by institutional investors. Comparatively, 65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. 2.8% of Amarin shares are held by insiders. Comparatively, 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Amarin and Arrowhead Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	0	3	8	0	2.73
Arrowhead Pharmaceuticals	0	2	10	0	2.83

Amarin presently has a consensus target price of $11.1818, suggesting a potential upside of 122.75%. Arrowhead Pharmaceuticals has a consensus target price of $85.3077, suggesting a potential upside of 26.10%. Given Amarin's higher possible upside, equities analysts clearly believe Amarin is more favorable than Arrowhead Pharmaceuticals.

Summary

Amarin beats Arrowhead Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Amarin vs. GW Pharmaceuticals Stock

Amarin (NASDAQ:AMRN) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Amarin and GW Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-2.69%	-2.70%	-1.72%
GW Pharmaceuticals	-11.05%	-7.46%	-6.13%

Valuation & Earnings

This table compares Amarin and GW Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$429.76 million	4.60	$-22,650,000.00	($0.07)	-71.71
GW Pharmaceuticals	$311.33 million	22.04	$-9,020,000.00	($0.24)	-912.08

GW Pharmaceuticals has lower revenue, but higher earnings than Amarin. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amarin has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500.

Institutional and Insider Ownership

37.8% of Amarin shares are owned by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amarin and GW Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	0	3	8	0	2.73
GW Pharmaceuticals	0	10	4	0	2.29

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 122.75%. GW Pharmaceuticals has a consensus price target of $204.0909, suggesting a potential downside of 6.77%. Given Amarin's stronger consensus rating and higher possible upside, research analysts plainly believe Amarin is more favorable than GW Pharmaceuticals.

Summary

Amarin beats GW Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Amarin vs. Ascendis Pharma A/S Stock

Amarin (NASDAQ:AMRN) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Amarin and Ascendis Pharma A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-2.69%	-2.70%	-1.72%
Ascendis Pharma A/S	-4,042.79%	-55.72%	-49.42%

Valuation & Earnings

This table compares Amarin and Ascendis Pharma A/S's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$429.76 million	4.60	$-22,650,000.00	($0.07)	-71.71
Ascendis Pharma A/S	$14.98 million	437.57	$-244,180,000.00	($5.25)	-23.23

Amarin has higher revenue and earnings than Ascendis Pharma A/S. Amarin is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amarin has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Institutional and Insider Ownership

37.8% of Amarin shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amarin and Ascendis Pharma A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	0	3	8	0	2.73
Ascendis Pharma A/S	0	1	11	0	2.92

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 122.75%. Ascendis Pharma A/S has a consensus price target of $187.6667, suggesting a potential upside of 53.89%. Given Amarin's higher possible upside, research analysts plainly believe Amarin is more favorable than Ascendis Pharma A/S.

Summary

Amarin beats Ascendis Pharma A/S on 9 of the 14 factors compared between the two stocks.

Amarin vs. TG Therapeutics Stock

Amarin (NASDAQ:AMRN) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Amarin and TG Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-2.69%	-2.70%	-1.72%
TG Therapeutics	-151,798.69%	-223.96%	-108.08%

Valuation & Earnings

This table compares Amarin and TG Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$429.76 million	4.60	$-22,650,000.00	($0.07)	-71.71
TG Therapeutics	$150,000.00	41,969.61	$-172,870,000.00	($1.83)	-24.47

Amarin has higher revenue and earnings than TG Therapeutics. Amarin is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amarin has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Institutional and Insider Ownership

37.8% of Amarin shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amarin and TG Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	0	3	8	0	2.73
TG Therapeutics	0	0	5	0	3.00

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 122.75%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 42.92%. Given Amarin's higher possible upside, research analysts plainly believe Amarin is more favorable than TG Therapeutics.

Summary

Amarin beats TG Therapeutics on 9 of the 14 factors compared between the two stocks.

Amarin vs. Ionis Pharmaceuticals Stock

Amarin (NASDAQ:AMRN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Institutional and Insider Ownership

37.8% of Amarin shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.8% of Amarin shares are owned by insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Amarin and Ionis Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	0	3	8	0	2.73
Ionis Pharmaceuticals	2	7	6	0	2.27

Amarin presently has a consensus price target of $11.1818, suggesting a potential upside of 122.75%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 42.00%. Given Amarin's stronger consensus rating and higher possible upside, research analysts plainly believe Amarin is more favorable than Ionis Pharmaceuticals.

Valuation & Earnings

This table compares Amarin and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$429.76 million	4.60	$-22,650,000.00	($0.07)	-71.71
Ionis Pharmaceuticals	$1.12 billion	5.12	$303.26 million	$2.08	19.61

Ionis Pharmaceuticals has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amarin and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarin	-2.69%	-2.70%	-1.72%
Ionis Pharmaceuticals	7.82%	6.57%	3.39%

Volatility & Risk

Amarin has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Summary

Ionis Pharmaceuticals beats Amarin on 9 of the 14 factors compared between the two stocks.